NeoGenomics (NEO) drew fresh attention after announcing that Alicia Olivo, EVP, General Counsel and Business Development, will step down as General Counsel on September 21, 2026, while remaining briefly to support the transition.

The leadership transition news comes during a strong run for NeoGenomics, with a 90 day share price return of 83.97% and a 1 year total shareholder return of 157.08%. However, the 5 year total shareholder return remains down 64.98%, suggesting momentum has picked up more recently.

If this kind of shift in sentiment has your attention, it could be a good moment to scan for other healthcare testing and treatment companies using our 40 healthcare AI stocks

After NeoGenomics' sharp rebound and stronger recent returns, the puzzle now is whether most of the easy gains are already in the rearview mirror or if the current valuation still leaves meaningful upside ahead.

Most Popular Narrative: 13.9% Undervalued

NeoGenomics last closed at $16.98 compared with a widely followed fair value estimate of $19.72, which frames the recent share price surge in a different light.

Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth.

Read the complete narrative. Read the complete narrative.

Want to see what underpins that higher fair value for NeoGenomics? The narrative leans heavily on recurring test volumes, richer test mix and a future profit multiple that assumes meaningful margin improvement. Curious how those moving parts are combined into one valuation story.

Result: Fair Value of $19.72 (UNDERVALUED)

However, NeoGenomics still faces pressure from declining nonclinical revenues and intense oncology testing competition, which could undermine the current valuation narrative if these trends worsen.

Another View: NeoGenomics Looks Expensive On Sales

The most popular NeoGenomics narrative leans on a higher fair value, yet the current P/S ratio of 2.8x tells a different story. It is higher than the US Healthcare industry at 1.5x, the peer average at 1.3x, and the fair ratio of 1.5x that the market could move towards. That gap points to valuation risk if sentiment cools and pricing starts to track sales more closely.

For anyone weighing these signals side by side, the question is whether the recent share price strength already reflects the long term potential or if the multiples still leave room for a different outcome.

Next Steps

If the mix of bullish narratives and valuation warnings around NeoGenomics feels mixed, now is a good time to study the data yourself and move fast. To understand what risks others are already watching, start with these: 2 important warning signs

Looking for more investment ideas beyond NeoGenomics?

Do not stop with NeoGenomics. Use this momentum to broaden your watchlist with other stocks that match the kind of qualities you want to focus on.

• Target potential mispricings by scanning companies that currently look out of favour yet financially robust using the 48 high quality undervalued stocks.
• Strengthen your downside protection by focusing on companies screened for resilient finances through the solid balance sheet and fundamentals stocks screener (50 results).
• Build a shortlist of potential compounders early by reviewing the screener containing 17 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.